deltatrials
Completed PHASE3 NCT00265811

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab

Sponsor: Federation Francophone de Cancerologie Digestive

Interventions Cetuximab Folfox
Updated 7 times since 2017 Last updated: Nov 5, 2020 Started: Nov 30, 2005 Primary completion: Nov 30, 2009 Completion: Jun 22, 2010

Listed as NCT00265811, this PHASE3 trial focuses on Colorectal Cancer and remains completed. Sponsored by Federation Francophone de Cancerologie Digestive, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE3

Show 2 earlier versions
  1. Jun 2018 — Dec 2020 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Federation Francophone de Cancerologie Digestive
Data source: Federation Francophone de Cancerologie Digestive

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • Avignon, France
  • Caen, France
  • Libourne, France
  • Paris, France
  • Saint-Brieuc, France
  • Valence, France